In a report released today, Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Plus Therapeutics (PSTV – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $2.50.
According to TipRanks, Lee CFA is an analyst with an average return of -16.5% and a 25.38% success rate. Lee CFA covers the Healthcare sector, focusing on stocks such as Plus Therapeutics, Gritstone Oncology, and Monopar Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Plus Therapeutics with a $39.50 average price target.
See today’s best-performing stocks on TipRanks >>
PSTV market cap is currently $6.23M and has a P/E ratio of -0.23.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. The lead drug product candidate in pipeline, DocePLUS™, is being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, and other professionals. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
Read More on PSTV:
- Is PSTV a Buy, Before Earnings?
- Plus Therapeutics reports positive Phase 1 trial data of rhenium obisbemeda
- Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
- Plus Therapeutics files to sell 1.5M shares of common stock for holders
- Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
